HUP0202969A2 - Sztatinok alkalmazása csontlebontó sejtek képződésének gátlására és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Sztatinok alkalmazása csontlebontó sejtek képződésének gátlására és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0202969A2 HUP0202969A2 HU0202969A HUP0202969A HUP0202969A2 HU P0202969 A2 HUP0202969 A2 HU P0202969A2 HU 0202969 A HU0202969 A HU 0202969A HU P0202969 A HUP0202969 A HU P0202969A HU P0202969 A2 HUP0202969 A2 HU P0202969A2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- statin
- osteoclasts
- statins
- compositions containing
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 210000002997 osteoclast Anatomy 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000002679 Alveolar Bone Loss Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 238000002650 immunosuppressive therapy Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Eljárás az oszteoklaszt képződés gátlására, amely az arra rászorulóemlősnek egy sztatin terápiásan hatékony mennyiségének adagolásábóláll, valamint gyógyszerkészítmények vagy kitek, amelyek a sztatinttartalmazzák, vagy egy eljárás a sztatin hatékony mennyiségének egyarra rászoruló emlősnek történő beadásával az oszteoklaszt képződésgátlására az olyan betegségek, mint a csontritkulás, a Paget- kór, azoszteolízis, bizonyos rosszindulatú daganatokat kísérő hiperkalcémia,a tökéletlen oszteogenezis, az oszteoarthritisz, az alveoláriscsontvesztés, valamint az immunszupresszív terápia mellékhatásai és akrónikus glukokortikoid kezelés mellékhatásai kezelésére vagymegelőzésére. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31845001P | 2001-09-10 | 2001-09-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0202969D0 HU0202969D0 (hu) | 2002-10-28 |
HUP0202969A2 true HUP0202969A2 (hu) | 2003-07-28 |
HUP0202969A3 HUP0202969A3 (en) | 2004-08-30 |
Family
ID=23238236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0202969A HUP0202969A3 (en) | 2001-09-10 | 2002-09-09 | Use of statins to inhibit formation of osteoclasts and pharmaceutical compositions containing them |
Country Status (13)
Country | Link |
---|---|
US (1) | US20030055101A1 (hu) |
EP (1) | EP1291017A3 (hu) |
JP (1) | JP2003104883A (hu) |
KR (1) | KR20030022725A (hu) |
CN (1) | CN1403081A (hu) |
BR (1) | BR0203656A (hu) |
CA (1) | CA2401319A1 (hu) |
HU (1) | HUP0202969A3 (hu) |
IL (1) | IL151571A0 (hu) |
NZ (1) | NZ521188A (hu) |
PL (1) | PL355958A1 (hu) |
TW (1) | TWI226238B (hu) |
ZA (1) | ZA200207233B (hu) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20084406B (en) * | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
CN1997374A (zh) * | 2004-06-23 | 2007-07-11 | 默克公司 | 雌激素受体调节剂 |
KR101224256B1 (ko) * | 2005-10-14 | 2013-01-18 | 한양대학교 산학협력단 | 레이저 기반의 이동 단말을 위한 다중채널의 장면구성 제어방법 및 장치 |
AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
WO2009064957A1 (en) * | 2007-11-14 | 2009-05-22 | Osteosphere, Llc | Development of a human colloidal bone graft material |
WO2009064917A2 (en) * | 2007-11-14 | 2009-05-22 | Osteosphere, Llc | Generation of an hla-negative osteogenic precursor cell line |
US20110086080A1 (en) * | 2007-11-14 | 2011-04-14 | Osteosphere, Llc | Ex-vivo production of human demineralized bone matrix |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2591782A1 (en) * | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
TWI542569B (zh) * | 2015-02-11 | 2016-07-21 | 高雄醫學大學 | 3,5-二羥基戊酸的類似物用於成骨作用 |
EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
CN109248338A (zh) * | 2018-11-16 | 2019-01-22 | 张浩淼 | 可吸收膜及其制备方法和应用、牙种植体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
WO1999045923A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
US20010025028A1 (en) * | 1998-03-13 | 2001-09-27 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
US6403637B1 (en) * | 1999-08-09 | 2002-06-11 | Univ Saint Louis | Methods of modulating matrix metalloproteinase activity and uses thereof |
AU2000701A (en) * | 1999-11-24 | 2001-06-04 | Bayer Aktiengesellschaft | Methods of ameliorating abnormal bone states |
-
2002
- 2002-08-27 EP EP02019026A patent/EP1291017A3/en not_active Withdrawn
- 2002-09-02 IL IL15157102A patent/IL151571A0/xx unknown
- 2002-09-03 CN CN02132146A patent/CN1403081A/zh active Pending
- 2002-09-04 NZ NZ521188A patent/NZ521188A/en unknown
- 2002-09-04 TW TW091120188A patent/TWI226238B/zh active
- 2002-09-05 CA CA002401319A patent/CA2401319A1/en not_active Abandoned
- 2002-09-09 HU HU0202969A patent/HUP0202969A3/hu unknown
- 2002-09-09 BR BR0203656-8A patent/BR0203656A/pt not_active IP Right Cessation
- 2002-09-09 ZA ZA200207233A patent/ZA200207233B/xx unknown
- 2002-09-10 JP JP2002264412A patent/JP2003104883A/ja active Pending
- 2002-09-10 KR KR1020020054503A patent/KR20030022725A/ko not_active Application Discontinuation
- 2002-09-10 PL PL02355958A patent/PL355958A1/xx not_active Application Discontinuation
- 2002-09-10 US US10/238,266 patent/US20030055101A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1403081A (zh) | 2003-03-19 |
EP1291017A2 (en) | 2003-03-12 |
PL355958A1 (en) | 2003-03-24 |
US20030055101A1 (en) | 2003-03-20 |
ZA200207233B (en) | 2004-03-09 |
EP1291017A3 (en) | 2003-07-02 |
BR0203656A (pt) | 2003-06-03 |
JP2003104883A (ja) | 2003-04-09 |
KR20030022725A (ko) | 2003-03-17 |
NZ521188A (en) | 2004-06-25 |
TWI226238B (en) | 2005-01-11 |
HU0202969D0 (hu) | 2002-10-28 |
CA2401319A1 (en) | 2003-03-10 |
IL151571A0 (en) | 2003-04-10 |
HUP0202969A3 (en) | 2004-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0202969A2 (hu) | Sztatinok alkalmazása csontlebontó sejtek képződésének gátlására és ezeket tartalmazó gyógyszerkészítmények | |
DK1914237T3 (da) | Antivirale fosfonatesterforbindelser | |
GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
LU91145I9 (hu) | ||
AU3249295A (en) | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 | |
IL149681A0 (en) | Polymorphic form of atorvstatin calcium | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
IL119989A0 (en) | Pharmaceutical compositions for oral treatment of multiple sclerosis | |
DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
BR9914718A (pt) | Formulações farmacêuticas de libertação controlada compreendendo um inibidor cgmp pde-5 | |
ZA943744B (en) | Therapeutic substituted guanidines | |
CA2234642A1 (en) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors | |
JO2663B1 (en) | Abandronate is a large dose | |
MXPA05011294A (es) | Compuestos de fosfonato anti-inflamatorios. | |
HUP0204097A2 (hu) | Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására | |
NZ326283A (en) | Diphenyl stilbenes as prodrugs to cox-2 inhibitors | |
IL111805A0 (en) | Pharmaceutical compositions comprising dimeticone for the treatment of aphthae | |
ATE208402T1 (de) | Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren | |
HK1082727A1 (en) | 2" oxo-voruscharin and derivatives thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |